FGFR2 and breast carcinoma: In contrast to gastric, endometrial, and breast cancers, where recurrent FGFR2 point mutations (e.g., S252W, N550K) have been documented [37], true mutations in GISTs are exceedingly rare, constituting <0.1% of cases in genomic profiling studies [38].